Invention Grant
- Patent Title: Heterocyclic amide compound
-
Application No.: US16333296Application Date: 2017-09-14
-
Publication No.: US10774083B2Publication Date: 2020-09-15
- Inventor: Takaharu Hirayama , Yasuhiro Hirata , Yusuke Tominari , Naoki Iwamura , Yusuke Sasaki , Moriteru Asano , Terufumi Takagi , Masanori Okaniwa , Shinichi Imamura
- Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
- Applicant Address: JP Osaka
- Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
- Current Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
- Current Assignee Address: JP Osaka
- Agency: Wenderoth, Lind & Ponack, L.L.P.
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@32ededca
- International Application: PCT/JP2017/033213 WO 20170914
- International Announcement: WO2018/052065 WO 20180322
- Main IPC: C07D401/04
- IPC: C07D401/04 ; C07D401/14 ; C07D473/28 ; C07D405/14 ; C07D413/14 ; C07D409/14 ; C07D417/14 ; C07D471/04 ; C07D473/40 ; C07D519/00 ; A61P35/00 ; A61K31/506 ; A61K31/444 ; A61K31/4439 ; C07D473/00 ; C07D473/32 ; A61K31/5377 ; A61K31/501 ; A61K31/52 ; A61P43/00 ; A61K31/437 ; C12N9/99
Abstract:
Provided is a heterocyclic amide compound that may have a PRS inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for PRS associated diseases and the like including cancer. A compound represented by the following formula (I): wherein a group represented by is a group represented by the following formula (II) or the following formula (III): and other symbols are as described in the DESCRIPTION, or a salt thereof.
Public/Granted literature
- US20190241566A1 HETEROCYCLIC AMIDE COMPOUND Public/Granted day:2019-08-08
Information query
